All In Biotech

Drug Trial Radar · NCT04995029

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-risk Opioid Use

Last checked: Nov 20, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 785 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

785

Actual

Start

Oct 26, 2021

Primary completion

Jun 26, 2024

Study completion Jun 26, 2024

Sponsor

Lead sponsor
Indivior Inc.Industry
Sponsor type
Industry
First posted
Aug 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the induction phase of the study is to compare treatment retention of participants following rapid induction or standard of care (SoC) induction onto extended-release buprenorphine. The primary objective of the maintenance phase is to compare the efficacy of 100 mg and 300 mg maintenance doses of extended-release buprenorphine administered every 4 weeks.

Conditions

  • Moderate to Severe Opioid-use Disorder

Interventions

  • Transmucosal BuprenorphineDrug

    Transmucosal (TM) buprenorphine as selected by the Investigator per local prescribing guidelines, administered either under the tongue (sublingual) or between the gum and cheek (buccal)

  • Extended-release BuprenorphineDrug

    Administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maintenance Phase: Percentage of Responders for Weekly Opioid Use Over Weeks 20 to 38Time frame: Weeks 20 to 38
  2. Induction Phase: Percentage of Participants Receiving Injection 2 at the Week 2 VisitTime frame: Week 2

Locations

29 sites in 2 countries. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Network, LLC

    Garden Grove, California

  • Asclepes Research Centers

    Panorama City, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • Bay Pines VA Healthcare System

    Bay Pines, Florida

  • Sarkis Clinical Trials

    Gainesville, Florida

  • Accel Research Sites- Lakeland Clinical Research Unit

    Lakeland, Florida

  • Behavioral Clinical Research, Inc

    Miami Lakes, Florida

  • Innovative Clinical Research Inc.

    North Miami, Florida

  • Clinical Neuroscience Solutions, Inc

    Orlando, Florida

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Hassman Research Institute

    Berlin, New Jersey

  • Center For Emotional Fitness

    Cherry Hill, New Jersey

  • ICAHN School of Medicine at Mount Sinai

    New York, New York

  • Duke Hospital

    Durham, North Carolina

  • Monroe Biomedical Research

    Monroe, North Carolina

  • Midwest Clinical Research

    Dayton, Ohio

  • Pahl Pharmaceutical Professionals LLC

    Oklahoma City, Oklahoma

  • SP Research, PLLC

    Oklahoma City, Oklahoma

  • Unity Clinical Research

    Oklahoma City, Oklahoma

  • Today Clinical Research

    Oklahoma City, Oklahoma

  • Clinical Research Associates of Central PA

    Altoona, Pennsylvania

  • Carolina Medical Research, LLC

    Clinton, South Carolina

  • Prisma Health ITOR Research Pharmacy

    Greenville, South Carolina

  • Carolina Medical Research, LLC

    Greenville, South Carolina

  • David Weitzman

    Myrtle Beach, South Carolina

  • Insite Clinical Research

    DeSoto, Texas

  • Progressive Clinical Research

    Bountiful, Utah

  • Alpine Research Organization

    Clinton, Utah

  • Centre for Addiction and Mental Health

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.